Moleculin Biotech, Inc. MBRX 深 滬

美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级

今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元

03-25 10:31

Moleculin Biotech reports FY results

Moleculin Biotech press release (MBRX): FY EPS of -$28.42. As of December 31, 2025, the Company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 mill...

03-20 02:59

Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per

03-19 21:38

Moleculin Biotech Updates Investors with New Corporate Presentation

Moleculin Biotech ( ($MBRX) ) just unveiled an update. On March 19, 2026, Molec...

03-19 21:28

Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary

Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary Moleculin Biotech Inc MBRX.OQ reported quarterly adjusted earnings of $13.04​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-9.32. The

03-19 19:59

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Moleculin Biotech reported encouraging early results from its MIRACLE trial, achieving a 40% preliminary blinded CRc rate in the first 30 patients with relapsed/refractory AML. The trial is evaluating Annamycin in combination with cytarabine (AnnAraC) and has met key milestones, including interim data readout. The company also expanded research into other cancers, includingglioblastoma and pancreatic cancer, and secured financial resources to adv...

03-19 12:36

Moleculin to Present at 38th Annual ROTH Conference

03-17 13:05

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Moleculin Biotech, Inc. announced the release of CEO Walter Klemp's latest segment on the CEO Corner platform, discussing progress in the MIRACLE Study evaluating Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (AML). The adaptive Phase 3 trial, designed with FDA input, includes an initial cohort of 45 patients. Enrollment and dosing are progressing as planned, with interim unblinding to assess...

03-11 13:00

Moleculin Biotech Raises Capital via Inducement Warrant Agreements

An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On Februar...

02-20 22:17

Moleculin Biotech Issues Unregistered Series H Inducement Warrants for Up to 6.37M Shares

Moleculin Biotech Issues Unregistered Series H Inducement Warrants for Up to 6.37M Shares Moleculin Biotech Inc. said it entered into warrant exercise inducement agreements with certain warrant holders, who agreed to exercise existing warrants for up to 2,122,652 shares at $3.90 per share. In exchan

02-20 21:51